Pius Baschera - Roche Holding Non-Executive Director
| RHHBY Stock | USD 30.25 0.23 0.77% |
Director
Prof. Dr. Pius Baschera was NonExecutive Director at Roche Holding Ltd since March 5, 2007. He is Member of the Corporationrationrate Governance and Sustainability Committee of the Company. From 1979 to 1981, Prof. Dr. Baschera was Vice President Production Controlling at Hilti Corporationrationration, Schaan, and from 1982 to 1984 he was Vice President Corporationrationrate Development Western Hemisphere at Hilti Inc. Tulsa, in the United States of America. In 1985, he became General Manager of Hilti AG and from 1985 until 1989, General Manager of Hilti Deutschland GmbH. From 1989 until 1990, Prof. Dr. Baschera was Vice President Market Region Europe 1 at Hilti Corporationrationration, Schaan, where he then worked as Member of Executive Board and Chief Financial Officer from 1990 until 1993 and Chief Executive Officer from 1994 until 2006. He then became Hilti Corporationrationrations Chairman of the Board of Directors in 2007. Prof since 2007.
| Age | 65 |
| Tenure | 17 years |
| Professional Marks | Ph.D |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Cohen | Journey Medical Corp | 53 | |
| Kathleen Sebelius | Journey Medical Corp | 69 | |
| Baowen Dong | China Pharma Holdings | 72 | |
| Frederick Craves | Journey Medical Corp | 72 | |
| Eugene Bauer | Journey Medical Corp | 75 | |
| John Longenecker | Pacira Pharmaceuticals | 70 | |
| Gene Bennett | China Pharma Holdings | 66 | |
| Keiichi Ando | Shionogi Co | 66 | |
| Kenji Matsuo | Shionogi Co | N/A | |
| Teppei Mogi | Shionogi Co | 59 | |
| Jake Nunn | Journey Medical Corp | 47 | |
| Akio Nomura | Shionogi Co | 82 | |
| Yvonne Greenstreet | Pacira Pharmaceuticals | 55 | |
| William Ringo | Journey Medical Corp | 72 | |
| Dennis Winger | Pacira Pharmaceuticals | 68 | |
| Heung Tsui | China Pharma Holdings | 56 | |
| Paul Hastings | Pacira Pharmaceuticals | 58 | |
| Mark McDade | Journey Medical Corp | 62 | |
| Yingwen Zhang | China Pharma Holdings | 68 | |
| Matthew Fust | Journey Medical Corp | 53 | |
| Katsuhiko Machida | Shionogi Co | 71 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
| Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
| Bruno Eschli, Head Relations | ||
| Silvia Ayyoubi, Head of Group HR | ||
| Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Beatrice Mauro, Non-Executive Director | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
| James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
| Gottlieb Keller, General Counsel and Corporate Secretary | ||
| Urs Jaisli, Chief Compliance Officer | ||
| Daniel ODay, COO of Pharmaceuticals division | ||
| Claudia Bockstiegel, G Counsel | ||
| DeAnne Julius, Non-Executive Director | ||
| Johannes MD, Head Devel | ||
| Karl Mahler, Head of Investor Relations | ||
| Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
| John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
| Claudia Dyckerhoff, Non-Executive Director | ||
| Fritz Gerber, Honorary Chairman of the Board | ||
| Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
| Julie Brown, Non-Executive Director | ||
| Richard Lifton, Non-Executive Director | ||
| Paul Bulcke, Non-Executive Director | ||
| Christoph Franz, Non-Executive Director | ||
| PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
| Pascale Schmidt, Chief Officer | ||
| Pius Baschera, Non-Executive Director | ||
| Peter Voser, Non-Executive Director | ||
| Bernard Poussot, Non-Executive Director | ||
| John Bell, Non-Executive Director | ||
| Andreas Oeri, Non-Executive Director | ||
| Alan Hippe, Chief Financial and IT Officer | ||
| William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
| F Hoffmann, IR Contact Officer | ||
| Severin Schwan, CEO and Executive Director | ||
| Anita Hauser, Non-Executive Director | ||
| Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 293.22 B | |||
| Shares Outstanding | 6.4 B | |||
| Shares Owned By Institutions | 1.27 % | |||
| Price To Earning | 17.56 X | |||
| Price To Book | 9.81 X | |||
| Price To Sales | 3.99 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Roche Holding in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Roche Holding's short interest history, or implied volatility extrapolated from Roche Holding options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding Ltd. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Roche Holding information on this page should be used as a complementary analysis to other Roche Holding's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |